Robert Halmosi

List of Publications by Year
in descending order

43 papers	2,297 citations	304368 22 h-index	253896 43 g-index
45 all docs	45 docs citations	45 times ranked	3442 citing authors

#	Article	IF	Citations
1	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2013, 15, 1173-1184.	2.9	533
2	Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clinical Hemorheology and Microcirculation, 2012, 50, 179-187.	0.9	288
3	Acute heart failure congestion and perfusion statusÂâ€“Âimpact of the clinical classification on inâ€hospital and longâ€term outcomes; insights from the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2019, 21, 1338-1352.	2.9	170
4	Effect of Poly(ADP-Ribose) Polymerase Inhibitors on the Ischemia-Reperfusion-Induced Oxidative Cell Damage and Mitochondrial Metabolism in Langendorff Heart Perfusion System. Molecular Pharmacology, 2001, 59, 1497-1505.	1.0	136
5	Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. JACC: Heart Failure, 2018, 6, 452-462.	1.9	94
6	Cardioprotective Effect of Resveratrol in a Postinfarction Heart Failure Model. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-10.	1.9	86
7	Unravelling the interplay between hyperkalaemia, reninâ€“angiotensinâ€“aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESCâ€HFAâ€EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 1378-1389.	2.9	83
8	Sexâ€•and ageâ€•related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 92-102.	2.9	81
9	In Vitro Antioxidant Properties of Pentoxifylline, Piracetam, and Vinpocetine. Clinical Neuropharmacology, 2002, 25, 37-42.	0.2	78
10	PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovascular Research, 2009, 83, 501-510.	1.8	61
11	Prevention of Doxorubicin-Induced Acute Cardiotoxicity by an Experimental Antioxidant Compound. Journal of Cardiovascular Pharmacology, 2005, 45, 36-43.	0.8	55
12	PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3Î² pathwayâ€†. Journal of Molecular and Cellular Cardiology, 2006, 41, 149-159.	0.9	52
13	The Role of Akt and Mitogen-Activated Protein Kinase Systems in the Protective Effect of Poly(ADP-Ribose) Polymerase Inhibition in Langendorff Perfused and in Isoproterenol-Damaged Rat Hearts. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 273-282.	1.3	44
14	Doxycycline protects against ROS-induced mitochondrial fragmentation and ISO-induced heart failure. PLoS ONE, 2017, 12, e0175195.	1.1	42
15	Akt activation induced by an antioxidant compound during ischemia-reperfusion. Free Radical Biology and Medicine, 2003, 35, 1051-1063.	1.3	41
16	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESCâ€EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 1424-1437.	2.9	36
17	Sacubitril/valsartan eligibility and outcomes in the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGMâ€HF trial, ESC guidelines, and real world. European Journal of Heart Failure, 2019, 21, 1383-1397.	2.9	35
18	The Effect of Resveratrol on the Cardiovascular System from Molecular Mechanisms to Clinical Results. International Journal of Molecular Sciences, 2021, 22, 10152.	1.8	35

#	Article	IF	Citations
19	PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3Î² and Several PKC Isoforms. PLoS ONE, 2014, 9, e102148.	1.1	29
20	Scavenger Effect of Experimental and Clinically Used Cardiovascular Drugs. Journal of Cardiovascular Pharmacology, 2001, 38, 745-753.	0.8	23
21	Effect of L-2286, a Poly(ADP-ribose)polymerase Inhibitor and Enalapril on Myocardial Remodeling and Heart Failure. Journal of Cardiovascular Pharmacology, 2008, 52, 253-261.	0.8	23
22	Regulation of Kinase Cascade Activation and Heat Shock Protein Expression by Poly(ADP-ribose) Polymerase Inhibition in Doxorubicin-induced Heart Failure. Journal of Cardiovascular Pharmacology, 2011, 58, 380-391.	0.8	23
23	A quinazoline-derivative compound with PARP inhibitory effect suppresses hypertension-induced vascular alterations in spontaneously hypertensive rats. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 935-944.	1.8	23
24	Navigating between Scylla and Charybdis: challenges and strategies for implementing guidelineâ€directed medical therapy in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 1999-2007.	2.9	22
25	Resveratrol Improves Heart Function by Moderating Inflammatory Processes in Patients with Systolic Heart Failure. Antioxidants, 2020, 9, 1108.	2.2	20
26	The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals. Cardiovascular Research, 2001, 52, 153-160.	1.8	18
27	Impact of a novel cardioprotective agent on the ischaemia-reperfusion-induced Akt kinase activation. Biochemical Pharmacology, 2003, 66, 2263-2272.	2.0	18
28	Mitochondrial protective effects of PARP-inhibition in hypertension-induced myocardial remodeling and in stressed cardiomyocytes. Life Sciences, 2021, 268, 118936.	2.0	17
29	2,2,5,5-Tetramethylpyrroline-Based Compounds in Prevention of Oxyradical-induced Myocardial Damage. Journal of Cardiovascular Pharmacology, 2002, 40, 854-867.	0.8	15
30	PARP inhibition and postinfarction myocardial remodeling. International Journal of Cardiology, 2016, 217, S52-S59.	0.8	14
31	Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol. Cardiovascular Therapeutics, 2020, 2020, 1-8.	1.1	14
32	Integrative characterization of chronic cigarette smoke-induced cardiopulmonary comorbidities in a mouse model. Environmental Pollution, 2017, 229, 746-759.	3.7	13
33	BGP-15 Protects against Heart Failure by Enhanced Mitochondrial Biogenesis and Decreased Fibrotic Remodelling in Spontaneously Hypertensive Rats. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-13.	1.9	12
34	Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats. PLoS ONE, 2017, 12, e0174401.	1.1	12
35	Drug-induced myocardial infarction in young patients. International Journal of Cardiology, 2005, 98, 169-170.	0.8	11
36	QRS Score: A Composite Index of Exercise-Induced Changes in the Q, R, and S Waves During Exercise Stress Testing in Patients with Ischemic Heart Disease. Annals of Noninvasive Electrocardiology, 2001, 6, 310-318.	0.5	10

#	Article	IF	Citations
37	Protective effects of the novel amine-oxidase inhibitor multi-target drug SZV 1287 on streptozotocin-induced beta cell damage and diabetic complications in rats. Biomedicine and Pharmacotherapy, 2021, 134, 111105.	2.5	9
38	The Effects of Bradykinin B1 Receptor Antagonism on the Myocardial and Vascular Consequences of Hypertension in SHR Rats. Frontiers in Physiology, 2019, 10, 624.	1.3	6
39	The Genetic Architecture of Hypertrophic Cardiomyopathy in Hungary: Analysis of 242 Patients with a Panel of 98 Genes. Diagnostics, 2022, 12, 1132.	1.3	4
40	Modulation of Mitochondrial Quality Control Processes by BGP-15 in Oxidative Stress Scenarios: From Cell Culture to Heart Failure. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-22.	1.9	3
41	Enhancement of Organ Regeneration in Animal Models by a Stem Cell-Stimulating Plant Mixture. Journal of Medicinal Food, 2010, 13, 599-604.	0.8	1
42	Interactions between iodinated contrast media and tissue plasminogen activator: In vitro comparison study. Clinical Hemorheology and Microcirculation, 2017, 66, 167-174.	0.9	1
43	l-arginine, asymmetric and symmetric dimethylarginine for early outcome prediction in unselected cardiac arrest victims: a prospective cohort study. Internal and Emergency Medicine, 2021, , 1.	1.0	1